In agreement with the original findings by Lynch and Daly (2002), a recent study comparing murine breast cancers driven by an ErbB2 transgene alone or in combination with an constitutively activated AKT transgene showed that the phosphorylation of Gab2 at Y452 was dramatically reduced in the latter [178]. This evidence concerns the gene ERBB2 and breast carcinoma.